Heron Therapeutics, Inc. (HRTX) earnings
HRTX earnings moved a median of -2.43% by the close. Quarterly and annual HRTX reports and results, each read against the price at its own news timestamp. Back to the HRTX overview →
29 measured HRTX earnings events.
Where these HRTX earnings landedvs 26 measured HRTX earnings reactions
| Middle 50% of HRTX earnings reactions | -8.33% to +4.02% |
|---|---|
| Median reaction (to close) | -2.43% |
| Measured reactions | 26 |
Point-in-time · zero look-ahead
Half of the 26 HRTX earnings events with a measured close landed between -8.33% and +4.02%; 35% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q HERON THERAPEUTICS, INC. For: Jun 30 | SEC filing · Form 10-Q | -7.41% | — | |
| Heron Therapeutics Announces Second Quarter 2026 Financial Results | Press release | -7.41% | — | |
| Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026 | Press release | +0.00% | -2.30% | |
| Form 10-Q HERON THERAPEUTICS, INC. For: Mar 31 | SEC filing · Form 10-Q | -8.26% | -12.36% | |
| Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance | Press release | -8.26% | -12.36% | |
| Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026 | Press release | +0.71% | +0.83% | |
| Form 10-K HERON THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form 10-K | +3.23% | -3.23% | |
| Form 10-Q HERON THERAPEUTICS, INC. For: Sep 30 | SEC filing · Form 10-Q | -1.70% | -2.56% | |
| Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 | Press release | -0.39% | -8.46% | |
| Form 10-Q HERON THERAPEUTICS, INC. For: Jun 30 | SEC filing · Form 10-Q | -2.43% | -8.33% | |
| Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025 | Press release | -2.43% | -8.33% | |
| Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025 | Press release | -1.10% | — | |
| Form 10-Q HERON THERAPEUTICS, INC. For: Mar 31 | SEC filing · Form 10-Q | +5.33% | -0.82% | |
| Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates | Press release | +5.33% | -0.82% | |
| Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025 | Press release | +2.23% | -1.79% | |
| Form 10-K HERON THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form 10-K | +4.50% | +8.47% | |
| Form 10-Q HERON THERAPEUTICS, INC. For: Sep 30 | SEC filing · Form 10-Q | +23.08% | +23.08% | |
| Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance | Press release | +23.08% | +23.08% | |
| Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024 | Press release | +1.72% | +3.45% | |
| Form 10-Q HERON THERAPEUTICS, INC. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -20.00% | |
| Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance | Press release | +0.00% | -20.00% | |
| Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 | Press release | -1.40% | +4.21% | |
| Form 10-Q HERON THERAPEUTICS, INC. For: Mar 31 | SEC filing · Form 10-Q | -10.13% | -4.65% | |
| Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates | Press release | -10.13% | -4.65% | |
| Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 | Press release | -0.35% | -6.03% | |
| Form 10-K HERON THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form 10-K | +6.43% | +7.50% | |
| Form 10-Q HERON THERAPEUTICS, INC. For: Sep 30 | SEC filing · Form 10-Q | +11.98% | +17.26% | |
| Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance | Press release | +11.98% | +17.26% | |
| Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023 | Press release | +0.00% | -10.24% |
Keep exploring
More HRTX: analyst actions → · SEC filings → · HRTX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Kala Pharmaceuticals, Inc. (KALA) | 248 | +0.41% | 56% |
| MELINTA THERAPEUTICS INC (MLNT) | 248 | -0.38% | 34% |
| Intra-Cellular Therapies Inc. (ITCI) | 247 | -0.04% | 44% |
| Avadel Pharmaceuticals plc - Ordinary Share (AVDL) | 246 | -0.16% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.